Phospho-GYS1 (Ser645) Antibody

What is Phospho-GYS1 (Ser645) Antibody and what epitopes does it recognize?

Phospho-GYS1 (Ser645) Antibody specifically detects endogenous levels of Glycogen Synthase 1 only when phosphorylated at Serine 645. The antibody recognizes the phosphorylated peptide sequence around the phosphorylation site of serine 645 (P-P-S(p)-P-S) derived from human Glycogen Synthase . This antibody is crucial for studying the regulatory state of glycogen synthase, as phosphorylation at this site contributes to the inactivation of the enzyme.

Note that there is some variation in the literature regarding the residue numbering - some sources refer to this site as Ser641 rather than Ser645, but they target the same functional phosphorylation site . This numbering discrepancy appears to be due to different reference sequences or splice variants being used.

What is the biological significance of GYS1 phosphorylation at Ser645?

Glycogen Synthase 1 (GYS1) catalyzes the addition of glucose monomers to the growing glycogen molecule through the formation of alpha-1,4-glycoside linkages, serving as the rate-limiting enzyme in glycogen synthesis . Phosphorylation at Ser645 (also referred to as Ser641 or site 3b) plays a critical role in regulating this activity.

The phosphorylation of GYS1 at multiple sites, including Ser645, leads to enzyme inactivation. According to recent structural studies, phosphoregulatory elements form a flexible inter-subunit "spike" region emanating from GS protomers, with phosphorylated S641 (site 3a) interacting with arginine residues from GS regulatory helices (arginine cradle) to maintain an inactive conformation .

Research indicates that:

• Phosphorylation at Ser-8 by AMPK inactivates enzyme activity

• Primed phosphorylation at Ser-657 (site 5) by CSNK2A1 and CSNK2A2 is required for inhibitory phosphorylation at Ser-641, Ser-645, Ser-649, and Ser-653 by GSK3A and GSK3B

• Dephosphorylation at Ser-641 and Ser-645 by PP1 activates the enzyme

How should I design experiments for studying GYS1 phosphorylation dynamics?

When designing experiments to study GYS1 phosphorylation dynamics, consider the following methodological approach:

• Experimental stimuli selection:

  • Insulin treatment (decreases phosphorylation)

  • Epinephrine or glucagon treatment (increases phosphorylation)

  • Glucose availability modulation

  • Exercise or muscle contraction (for in vivo or tissue studies)

• Time course considerations:

  • Include multiple time points (5, 15, 30, 60 minutes) to capture phosphorylation kinetics

  • Consider both acute and chronic treatment paradigms

• Control conditions:

  • Use λ phosphatase-treated samples as negative controls for phospho-specific antibodies

  • Include total GYS1 antibody detection in parallel experiments

  • Consider the use of phosphorylation site mutants (e.g., S645A) where possible

• Complementary techniques:

  • Combine phospho-antibody detection with functional assays of glycogen synthase activity

  • Use citrate synthase activity assay as a control for metabolic activity

For metabolic studies, plasma insulin measurements can be performed after overnight fasting and at 5 and 25 minutes after glucose injection, using appropriate blood collection methods (EDTA-coated tubes) and analysis with validated insulin detection kits .

What are the optimal conditions for Western blot using Phospho-GYS1 (Ser645) Antibody?

For optimal Western blot results with Phospho-GYS1 (Ser645) Antibody, follow these validated protocols:

Sample Preparation:

• Use fresh cell or tissue lysates with phosphatase inhibitors

• For negative controls, treat a portion of your samples with lambda phosphatase

Gel Electrophoresis:

• Use 5-20% SDS-PAGE gel at 70V (stacking)/90V (resolving) for 2-3 hours

• Load 30μg of protein per lane under reducing conditions

Protein Transfer:

• Transfer to nitrocellulose membrane at 150mA for 50-90 minutes

Blocking and Antibody Incubation:

• Block with 5% non-fat dry milk in TBS or TBST for 1.5 hours at room temperature

• Incubate with primary antibody at 1:500-1:2000 dilution overnight at 4°C

• Wash with TBS-0.1% Tween, 3 times for 5 minutes each

• Incubate with appropriate HRP-conjugated secondary antibody (goat anti-rabbit IgG-HRP) at 1:500-1:5000 dilution for 1-1.5 hours at room temperature

Detection:

• Develop using an Enhanced Chemiluminescent detection (ECL) kit

• The expected band size for Phospho-GYS1 is approximately 84-90 kDa

Notes on specific cell types:
Validated cell lines include HeLa, RT4, SIHA, and PC-3 cells .

How can I validate the specificity of Phospho-GYS1 (Ser645) Antibody?

To validate the specificity of Phospho-GYS1 (Ser645) Antibody, implement the following strategies:

• Phosphatase treatment controls:

  • Treat cell lysates with lambda phosphatase to remove phosphate groups

  • Compare antibody reactivity between treated and untreated samples

  • The signal should be substantially reduced or eliminated in phosphatase-treated samples

• Phosphorylation-dependent stimulation:

  • Treat cells with stimuli known to modify phosphorylation status:

    • Insulin (reduces phosphorylation)

    • Epinephrine or glucagon (increases phosphorylation)

  • Observe the expected changes in signal intensity

• Phospho-blocking peptide competition:

  • Pre-incubate the antibody with the phosphopeptide immunogen

  • The specific signal should be blocked in Western blot or other applications

• Cross-validation with multiple phospho-specific antibodies:

  • Compare results with antibodies targeting different but related phosphorylation sites (e.g., Ser641)

  • Use dual phospho-specific antibodies (e.g., Ser641/Ser645)

• Genetic validation:

  • Use GYS1 knockdown or knockout models as negative controls

  • Employ phospho-site mutants (S645A) to confirm specificity

The specificity of the antibody can be confirmed when these controls demonstrate appropriately differential detection between phosphorylated and non-phosphorylated states of GYS1.

What is the structural mechanism of GYS1 inactivation by phosphorylation?

Recent structural studies have revealed critical insights into the mechanism of GYS1 inactivation by phosphorylation:

A 2021 cryo-EM study provided the first structure of phosphorylated human GS-GN complex, revealing an autoinhibited GS tetramer flanked by two GN dimers . Key structural findings include:

• Phosphoregulatory apparatus structure:

  • Phosphoregulatory elements form a flexible inter-subunit "spike" region

  • This spike emanates from two GS protomers

  • Phosphorylated S641 (site 3a) interacts with arginine residues from GS regulatory helices, forming an "arginine cradle"

  • These interactions maintain GS in an inactive conformation

• GS-GN complex organization:

  • Mass photometry measurements indicate a predominant molecular weight of 473 ± 43 kDa for the GS-GN complex, suggesting a 4:4 stoichiometry

  • Negative stain electron microscopy confirms that two GN dimers interact with a GS tetramer, one on either side

  • Surprisingly, GN dimers do not engage GS dimers identically, with one GN tilted slightly toward one of the GS protomers

• Regulatory phosphorylation network:

  • Multiple phosphorylation sites (including Ser641/645) work cooperatively

  • Primed phosphorylation at one site facilitates subsequent phosphorylation at other sites

  • This creates a hierarchical regulatory system for fine-tuning GYS1 activity

This structural understanding helps explain how phosphorylation at sites like Ser645 contributes to maintaining GYS1 in an inactive state until appropriate metabolic signals trigger its activation through dephosphorylation.

How do GYS1 phosphorylation patterns change in metabolic disorders?

GYS1 phosphorylation status is significantly altered in various metabolic disorders, reflecting dysregulation of glycogen metabolism:

• Diabetes and insulin resistance:

  • Increased basal phosphorylation of GYS1 at Ser641/645 in insulin-resistant states

  • Impaired insulin-stimulated dephosphorylation

  • This contributes to reduced glycogen synthesis capacity in muscle tissues

  • Modification of Akt2 by 4-hydroxynonenal can inhibit insulin-dependent Akt signaling, affecting downstream GYS1 regulation

• Muscle glycogen storage diseases:

  • Mutations in GYS1 are associated with muscle glycogen storage disease

  • Pathological GYS1 deficiency can cause muscle glycogen storage disease type 0 and death

  • Altered phosphorylation patterns may compensate for or exacerbate underlying genetic defects

• Cancer metabolism:

  • GYS1 is rapidly induced under hypoxic conditions

  • Positive correlation with glycogen accumulation in glioblastoma, breast, and colon cancer cell lines

  • Changed phosphorylation patterns may reflect metabolic reprogramming in tumors

• Metabolic dysregulation in other diseases:

  • Recent research has identified altered metabolic phenotypes in dysferlin-deficient muscles

  • This includes mitochondrial abnormalities that may influence glycogen metabolism

Understanding these phosphorylation changes can provide insights into disease mechanisms and potential therapeutic targets for metabolic disorders.

What is the interplay between different phosphorylation sites on GYS1?

GYS1 regulation involves a complex network of phosphorylation sites that interact hierarchically:

This intricate phosphorylation network enables fine-tuned regulation of GYS1 activity in response to various metabolic signals and physiological states.

Why might I see discrepancies when using different Phospho-GYS1 antibodies?

Several factors can contribute to discrepancies when using different Phospho-GYS1 antibodies:

• Residue numbering variations:

  • The same phosphorylation site may be referenced as either Ser641 or Ser645 in different antibodies

  • This numbering discrepancy results from different reference sequences or splice variants

• Epitope specificity differences:

  • Some antibodies recognize single phosphorylation sites (e.g., only Ser645)

  • Others detect dual phosphorylation (e.g., both Ser641 and Ser645)

  • The surrounding sequence context recognized by each antibody may differ

• Antibody format and production method:

  • Differences between polyclonal and monoclonal antibodies:

    • Polyclonals may recognize multiple epitopes

    • Monoclonals have higher specificity for a single epitope

  • Recombinant vs. animal-derived antibodies may have different characteristics

• Cross-reactivity profiles:

  • Varying degrees of species cross-reactivity (human, mouse, rat)

  • Potential cross-reactivity with other phosphoproteins

To address these discrepancies:

• Always validate antibodies with appropriate controls

• Clearly document which antibody was used when reporting results

• Consider using multiple antibodies targeting different epitopes to confirm findings

• When comparing to literature, note which specific antibody was used in previous studies

What are the optimal controls for GYS1 phosphorylation studies?

For robust GYS1 phosphorylation studies, incorporate these essential controls:

• Phosphorylation state controls:

  • Positive control: Samples from cells/tissues treated with agents known to increase GYS1 phosphorylation (e.g., epinephrine)

  • Negative control: Lambda phosphatase-treated samples to remove phosphate groups

  • Total GYS1 control: Parallel detection with a phosphorylation-independent GYS1 antibody

• Specificity controls:

  • Phosphopeptide competition: Pre-incubate antibody with the immunizing phosphopeptide

  • Non-phosphopeptide competition: Pre-incubate with non-phosphorylated version of the same peptide

  • Phospho-site mutants: Where available, use S645A mutant GYS1 constructs

• Sample preparation controls:

  • Phosphatase inhibitor control: Compare samples prepared with and without phosphatase inhibitors

  • Loading control: Use housekeeping proteins (β-actin, GAPDH) or total protein stains

  • Cross-sample normalization: Include a common reference sample across multiple blots

• Experimental validation controls:

  • Insulin response: Verify expected decrease in phosphorylation with insulin treatment

  • Metabolic enzyme control: Consider citrate synthase activity as a control for metabolic effects

  • Time course sampling: Include multiple time points to capture phosphorylation dynamics

Implementing these controls will significantly enhance the reliability and interpretability of GYS1 phosphorylation data.

How can I quantify changes in GYS1 phosphorylation accurately?

For accurate quantification of GYS1 phosphorylation changes, implement these methodological approaches:

• Normalization strategies:

  • Phospho/Total ratio method:

    • Probe parallel blots with phospho-specific and total GYS1 antibodies

    • Calculate the ratio of phospho-GYS1 to total GYS1 signal for each sample

    • This controls for variations in total GYS1 expression or loading

  • Loading control normalization:

    • Normalize phospho-GYS1 signal to consistent housekeeping proteins

    • Options include β-actin, GAPDH, β-tubulin, or total protein stains

    • Particularly important when total GYS1 levels may change

• Quantification techniques:

  • Densitometry analysis:

    • Use calibrated imaging systems with appropriate software

    • Ensure signal is within linear detection range

    • Subtract background from each measurement

  • Fluorescence-based detection:

    • Consider dual-color fluorescent detection for simultaneous phospho and total measurement

    • Provides better dynamic range than chemiluminescence

    • Reduces inter-blot variability

• Alternative quantitative approaches:

  • ELISA-based methods:

    • Commercially available cell-based ELISA kits for Phospho-GYS1 (Ser645)

    • Enables high-throughput analysis

    • More quantitative than Western blot

  • Mass spectrometry:

    • For absolute quantification of phosphopeptides

    • Can distinguish between different phosphorylation sites

    • Requires specialized equipment and expertise

• Data analysis considerations:

  • Statistical approach:

    • Use appropriate statistical tests for experimental design

    • Account for biological and technical replicates

    • Consider normality of data distribution

  • Reporting standards:

    • Present both raw and normalized data

    • Include sample size and number of independent experiments

    • Report specific antibody dilutions and detection methods used

By combining these approaches, researchers can achieve more accurate and reproducible quantification of GYS1 phosphorylation dynamics.

What are the latest structural insights into GYS1 regulation?

Recent breakthrough structural studies have transformed our understanding of GYS1 regulation:

A 2021 cryo-electron microscopy study provided the first structure of phosphorylated human GS-GN complex, revealing critical insights into GYS1 regulation at the molecular level :

• Novel structural elements:

  • Discovery of a phosphoregulatory inter-subunit "spike" region

  • Identification of an "arginine cradle" that interacts with phosphorylated residues

  • Visualization of how phosphorylation physically maintains the inactive conformation

• Complex stoichiometry and organization:

  • Mass photometry measurements confirmed a 4:4 stoichiometry for the GS-GN complex

  • The structure revealed two GN dimers flanking a GS tetramer

  • Asymmetric engagement of GN dimers with the GS tetramer

• Structural basis for hierarchical phosphorylation:

  • The structure explains how primed phosphorylation at one site facilitates additional phosphorylation events

  • Provides physical understanding of the functional interactions between different phosphorylation sites

These structural insights offer unprecedented opportunities for targeted intervention in glycogen metabolism disorders and provide a framework for understanding how mutations in GYS1 lead to disease states.

How is GYS1 phosphorylation being targeted in therapeutic development?

The critical role of GYS1 phosphorylation in metabolic regulation has made it an attractive target for therapeutic development:

• Metabolic disease approaches:

  • Type 2 diabetes interventions targeting the insulin signaling pathway to enhance GYS1 dephosphorylation

  • GSK3 inhibitors that reduce inhibitory phosphorylation of GYS1

  • PP1 activators to enhance dephosphorylation and activation of GYS1

• Muscle glycogen storage diseases:

  • Precision medicine approaches targeting specific phosphorylation sites affected by GYS1 mutations

  • Gene therapy strategies to correct underlying genetic defects

  • Metabolic bypass strategies that compensate for altered GYS1 activity

• Cancer metabolism:

  • Targeting hypoxia-induced GYS1 upregulation in tumors

  • Modulating glycogen metabolism as part of broader metabolic reprogramming strategies

  • Combination approaches with other metabolic pathway interventions

• Emerging therapeutic modalities:

  • Antisense oligonucleotides targeting GYS1 expression

  • Small molecule stabilizers/destabilizers of specific GYS1 phosphorylation states

  • Peptide-based modulators of GYS1-GN interactions

Future therapeutic development will likely benefit from the recent structural insights into the GYS1-GN complex, enabling more targeted approaches to modulating glycogen synthase activity through its phosphorylation state.

What emerging technologies will advance GYS1 phosphorylation research?

Several cutting-edge technologies are poised to transform GYS1 phosphorylation research:

• Advanced structural biology approaches:

  • Cryo-electron tomography for visualizing GYS1 complexes in cellular contexts

  • Time-resolved structural studies to capture phosphorylation-dependent conformational changes

  • Integrative structural biology combining multiple techniques for complete models

• Single-molecule techniques:

  • FRET-based sensors for tracking GYS1 phosphorylation in living cells

  • Single-molecule enzyme kinetics to understand how phosphorylation affects catalytic rate

  • Super-resolution microscopy for visualizing GYS1 localization and interactions

• Proteomic innovations:

  • Phosphoproteomics to map the complete phosphorylation landscape of GYS1

  • Proximity labeling to identify contextual interaction partners

  • Top-down proteomics for characterizing combinatorial post-translational modifications

• Genome engineering and high-throughput screening:

  • CRISPR-based phosphosite mutant libraries

  • Phosphorylation-specific reporter systems for high-throughput screening

  • Patient-derived cellular models for personalized disease research

• Computational and AI approaches:

  • Molecular dynamics simulations of phosphorylation effects

  • Machine learning for predicting functional outcomes of phosphorylation patterns

  • Systems biology modeling of glycogen metabolism networks